LB Pharmaceuticals Inc (NASDAQ:LBRX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the thirteen brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $57.40.
LBRX has been the topic of a number of recent analyst reports. Piper Sandler reissued an “overweight” rating and issued a $78.00 price objective on shares of LB Pharmaceuticals in a research note on Monday, August 3rd. HC Wainwright restated a “buy” rating on shares of LB Pharmaceuticals in a report on Monday, October 12th. Zacks Research upgraded shares of LB Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 10th. Wall Street Zen downgraded LB Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday, November 8th. Finally, Raymond James Financial raised shares of LB Pharmaceuticals to a “buy” rating in a report on Monday, October 12th.
Read Our Latest Stock Report on LBRX
LB Pharmaceuticals Stock Performance
Shares of NASDAQ:LBRX opened at $40.06 on Friday. LB Pharmaceuticals has a 52-week low of $15.19 and a 52-week high of $50.16. The company has a fifty day moving average of $39.73 and a 200-day moving average of $33.77. The company has a market capitalization of $1.30 billion, a PE ratio of -8.67 and a beta of 0.82.
LB Pharmaceuticals (NASDAQ:LBRX – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.18). On average, equities analysts forecast that LB Pharmaceuticals will post -6.05 EPS for the current fiscal year.
Institutional Trading of LB Pharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the company. Aquatic Capital Management LLC increased its stake in LB Pharmaceuticals by 311.9% in the 3rd quarter. Aquatic Capital Management LLC now owns 24,530 shares of the company’s stock worth $941,000 after acquiring an additional 18,574 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of LB Pharmaceuticals by 67.3% during the third quarter. Goldman Sachs Group Inc. now owns 964,373 shares of the company’s stock valued at $37,013,000 after buying an additional 387,917 shares during the last quarter. Great Point Partners LLC increased its stake in LB Pharmaceuticals by 29.4% in the 3rd quarter. Great Point Partners LLC now owns 410,420 shares of the company’s stock worth $15,752,000 after purchasing an additional 93,199 shares during the period. Bellevue Group AG bought a new stake in LB Pharmaceuticals during the 3rd quarter valued at $27,461,000. Finally, Integral Health Asset Management LLC boosted its holdings in shares of LB Pharmaceuticals by 213.3% during the third quarter. Integral Health Asset Management LLC now owns 470,000 shares of the company’s stock worth $18,039,000 after purchasing an additional 320,000 shares during the period.
About LB Pharmaceuticals
LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for serious neuropsychiatric disorders. Its research focuses on medicines intended to address conditions with significant unmet treatment needs. The company’s lead candidate, LB-102, is an oral investigational drug being studied for schizophrenia. LB Pharmaceuticals has also identified other psychiatric conditions, including bipolar disorder, as potential areas of development. LB-102 has not been approved for commercial use, and its safety and effectiveness have not been established by regulators.
Featured Articles
- Five stocks we like better than LB Pharmaceuticals
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for LB Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LB Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
